TheraRadar
← Back
Data updated: May 24, 2026

Sanofi

SNY Big Pharma
MetabolicOncologyInfectious Disease Execution: Good

French pharma with diverse portfolio spanning vaccines (Fluzone), immunology (Dupixent), and rare diseases (Fabrazyme). Growing focus on immunology.

$46.1B
Revenue (2024)
$130.0B
Market Cap
-
Trials
2
New Drugs (2yr)
Modality:
19 Small Molecules 35 Biologics
Novel Drugs (2017-2025):
7 Novel Approvals 4 First-in-Class 6 Orphan Drug 2 Breakthrough

Sanofi at a Glance

  • Fast trial execution (19 months median completion)

Recent FDA Approvals

New drug approvals (NDA/BLA) in the last 2 years. Shows novel drugs only, excluding generics and label supplements.

WAYRILZ NDA
2025-08-29
rilzabrutinib
Immune Thrombocytopenia
QFITLIA NDA
2025-03-28
fitusiran sodium
Hemophilia A

Therapeutic Areas

Disease areas where this company has approved drugs and active pipeline. Weighted by commercial stage: approved drugs count most, followed by late-stage trials.

Metabolic 30%
7 drugs Phase 3: 70 Phase 2: 12 Phase 1: 100
Oncology 27%
9 drugs Phase 3: 34 Phase 2: 57 Phase 1: 101
Infectious Disease 17%
1 drugs Phase 3: 44 Phase 2: 24 Phase 1: 26
Immunology 14%
2 drugs Phase 3: 23 Phase 2: 37 Phase 1: 28
Cardiovascular 11%
4 drugs Phase 3: 27 Phase 2: 10 Phase 1: 15

Pipeline Snapshot

Active clinical trials across all therapeutic areas. Data from ClinicalTrials.gov.

198
Phase 3
140
Phase 2
270
Phase 1

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • • ALTUVIIIO leads revenue
  • • 5 key drugs tracked
View revenue breakdown →

Trial Catalysts

  • • Metabolic pipeline focus
  • • Phase 3 readout tracking
View full pipeline →

Patent Risk

  • • Patent expiration timeline
  • • Revenue at risk analysis
View patent timeline →

Compare Companies

  • • Side-by-side pipeline analysis
  • • Revenue & market share comparison
Compare with competitor →

Execution Intelligence

  • • Phase 3: 224/312 completed
  • • Speed: 19 months avg
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling

How We Calculate These Metrics

Execution Quality Score

Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.

What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.

  • Excellent (80%+): Top-tier execution, most trials reach planned endpoints
  • Good (60-79%): Strong execution with occasional early terminations
  • Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
  • Needs Improvement (under 40%): High termination rates, execution challenges